Cyclophosphamide and the taste system: Effects of dose fractionation and amifostine on taste cell renewal

Abstract

Chemotherapy often causes side effects that include disturbances in taste functions. Cyclophosphamide (CYP) is a chemotherapy drug that, after a single dose, elevates murine taste thresholds at times related to drug-induced losses of taste sensory cells and disruptions of proliferating cells that renew taste sensory cells. Pretreatment with amifostine can protect the taste system from many of these effects. This study compared the effects of a single dose (75 mg/kg) of CYP with effects generated by fractionated dosing of CYP (5 doses of 15 mg/kg), a dosing approach often used during chemotherapy, on the taste system of mice using immunohistochemistry. Dose fractionation prolonged the suppressive effects of CYP on cell proliferation responsible for renewal of taste sensory cells. Fractionation also reduced the total number of cells and the proportion of Type II cells within taste buds. The post-injection time of these losses coincided with the life span of Type I and II taste cells combined with lack of replacement cells. Fractionated dosing also decreased Type III cells more than a single dose, but loss of these cells may be due to factors related to the general health and/or cell renewal of taste buds rather than the life span of Type III cells. In general, pretreatment with amifostine appeared to protect taste cell renewal and the population of cells within taste buds from the cytotoxic effects of CYP with few observable adverse effects due to repeated administration. These findings may have important implications for patients undergoing chemotherapy.

The Anti-Inflammatory Drug Aspirin Does Not Protect Against Chemotherapy-Induced Memory Impairment by Paclitaxel in Mice

“…To investigate this, we quantified the effect of chemotherapy treatment on taste bud density and taste receptor expression. Patients report a loss of taste perception after chemotherapy ( 27 , 28 ), which has been attributed to loss of taste buds and the receptors that signal flavor perception ( 29 , 30 ). Perception of sweet flavors are determined by receptors encoded by Tas1r2 and Tas1r3 genes, whereas umami flavors involve Tas1r1 and Tas1r3 genes.…”

Drinking Ice-Cold Water Reduces the Severity of Anticancer Drug-Induced Taste Dysfunction in Mice

“…One possible explanation for our observations is that TPF targets taste stem/progenitor cells at the basal part of the taste buds where cell proliferation is frequently observed ( Figure 3 ). Sonic hedgehog (Shh) is a key player in the formation and maintenance of taste buds, and its expression is preferentially restricted to the basal region of taste buds [ 39 , 40 ]. Vismodegib and sonidegib, which are antagonists of Shh that exert an anticancer effect via a different mechanism to TPF, directly alter Shh/smoothened (Smo)/glioma-associated oncogene homolog (Gli) signaling in the taste buds, resulting in a decrease in taste bud size, lower expression of taste cell markers (such as PLCβ2, T1R3 and gustducin), and a reduction in the responses of taste buds and taste nerves to five basic tastants [ 41 , 42 ].…”

Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs

“…In the liver, microsomal mixed-function oxidases convert cyclophosphamide into aldophosphamide, which is then processed by cytochrome P450 inside the tumor, yielding phosphoramide mustard and acrolein [73]. Acrolein and phosphoramide mustard are both cytotoxic, but phosphoramide is an alkylating agent that crosslinks DNA to prevent replication [74], implying that cyclophosphamide treatment is especially harmful to actively dividing cells, such as cancer cells [75]. Women with TNBC exhibit a higher rate of pCR compared to other breast cancer subtypes [76], indicating that the combined treatment of docetaxel and cyclophosphamide regimen is more suitable to treat TNBC.…”